Literature DB >> 10547579

Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology.

R Gradini1, M Realacci, A Ginepri, G Naso, C Santangelo, O Cela, P Sale, A Berardi, E Petrangeli, M Gallucci, F Di Silverio, M A Russo.   

Abstract

The expression of nitric oxide synthase (NOS) isoforms has been investigated in normal (three subjects) and benign hyperplastic prostate (ten patients) by immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR). The inducible NOS (iNOS or NOS-2) is not detected in normal prostate, while it is expressed in the prostate of all benign prostatic hyperplasia (BPH) patients, even in the absence of prostatitis or systemic signs of an inflammatory condition. This suggests that sex hormones may be involved in iNOS induction and that there may be a role for NO in the pathogenesis of BPH. Constitutive NOSs (nNOS and eNOS) are expressed in both normal and hyperplastic prostate and are co-expressed in epithelial cells. eNOS, however, is present mainly in the basal layer cells; nNOS seems abundantly expressed in the more superficial cells of the affected prostate. This indicates that the switching between the two constitutive isoforms may be part of the usual process of cell differentiation from the basal to the secretory layer of the epithelium. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547579     DOI: 10.1002/(SICI)1096-9896(199910)189:2<224::AID-PATH422>3.0.CO;2-K

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  21 in total

Review 1.  Male lower urinary tract symptoms: treatment with a-blockers, 5-a-reductase inhibitors, antimuscarinics, or a combination.

Authors:  Rodney A Appell
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

2.  Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.

Authors:  Steven A Kaplan; Ricardo R Gonzalez
Journal:  Rev Urol       Date:  2007

Review 3.  The functional role of reactive stroma in benign prostatic hyperplasia.

Authors:  Isaiah G Schauer; David R Rowley
Journal:  Differentiation       Date:  2011-06-12       Impact factor: 3.880

Review 4.  Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?

Authors:  Petter Hedlund
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

5.  Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia.

Authors:  Koo Han Yoo; Su Kang Kim; Joo-Ho Chung; Sung-Goo Chang
Journal:  Asian J Androl       Date:  2010-06-21       Impact factor: 3.285

6.  Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer.

Authors:  Meltem Ozlen Dillioglugil; Haluk Mekık; Bahar Muezzinoglu; T Alp Ozkan; Cennet Gural Demir; Ozdal Dillioglugil
Journal:  Int Urol Nephrol       Date:  2012-06-19       Impact factor: 2.370

7.  Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.

Authors:  Dean S Elterman; Bilal Chughtai; Richard K Lee; Alexis E Te; Steven A Kaplan
Journal:  Rev Urol       Date:  2012

8.  Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells.

Authors:  Ying Wai Lam; Yong Yuan; Jared Isaac; C V Suresh Babu; Jarek Meller; Shuk-Mei Ho
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

9.  Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.

Authors:  Altug Tuncel; Varol Nalcacioglu; Kemal Ener; Yilmaz Aslan; Omur Aydin; Ali Atan
Journal:  World J Urol       Date:  2009-10-24       Impact factor: 4.226

10.  Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases.

Authors:  Eswar Shankar; Natarajan Bhaskaran; Gregory T MacLennan; Guiming Liu; Firouz Daneshgari; Sanjay Gupta
Journal:  J Urol Res       Date:  2015-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.